[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654009":3},{"organization":4,"outcomesModule":7,"designInfo":32,"detailedDescription":41,"studyPopulation":31,"armGroups":42,"interventions":53,"overallOfficials":59,"centralContacts":63,"locations":72,"responsibleParty":90,"collaborators":31,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":94,"sex":100,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":31,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":120,"whyStopped":31,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"University of North Carolina, Chapel Hill","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":31},[9,13],{"measure":10,"description":11,"timeFrame":12},"Repeated Sprint Ability Peak Power","Peak power (Watts) measured during a repeated sprint ability cycling test.","Change from baseline to 4 weeks post-supplementation.",{"measure":14,"description":15,"timeFrame":12},"Fatigue Index","Fatigue index (%) calculated from repeated sprint ability testing.",[17,21,24,28],{"measure":18,"description":19,"timeFrame":20},"Skeletal Muscle Oxygen Recovery","Recovery rate constant of skeletal muscle oxygen consumption following exercise measured by near-infrared spectroscopy and arterial occlusion procedures.","Change from baseline to 4 weeks post-supplementation",{"measure":22,"description":23,"timeFrame":20},"Executive Function","Executive function measured using the NIH Toolbox Flanker Inhibitory Control and Attention Test.",{"measure":25,"description":26,"timeFrame":27},"Working Memory","Working memory measured using the NIH Toolbox List Sorting Working Memory Test.","Change in baseline to 4 weeks post-supplementation.",{"measure":29,"description":30,"timeFrame":20},"Brain Creatine Concentration","Brain phosphocreatine and related bioenergetic metabolites assessed using phosphorus magnetic resonance spectroscopy (³¹P-MRS) in the imaging subsample",null,{"allocation":33,"interventionModel":34,"interventionModelDescription":35,"primaryPurpose":6,"observationalModel":31,"timePerspective":31,"maskingInfo":36},"RANDOMIZED","PARALLEL","Participants will be randomized in a 1:1 ratio to receive either 5 g\u002Fday or 10 g\u002Fday creatine monohydrate for four weeks.",{"masking":37,"maskingDescription":31,"whoMasked":38},"DOUBLE",[39,40],"PARTICIPANT","INVESTIGATOR","Postpartum women frequently experience changes in physical performance, recovery, cognition, sleep quality, and mood. Creatine supplementation may enhance energy availability in skeletal muscle and brain tissue, potentially improving exercise performance, recovery, and cognitive function. This study will enroll 40 postpartum women and randomly assign participants in a 1:1 ratio to receive either 5 g\u002Fday or 10 g\u002Fday of creatine monohydrate for four weeks in a double-blind fashion. Assessments will be conducted before and after supplementation and will include repeated sprint ability testing, skeletal muscle oxygen recovery, and cognitive testing. A subsample of 20 participants will undergo magnetic resonance spectroscopy to assess brain creatine stores.",[43,49],{"label":44,"type":45,"description":46,"interventionNames":47},"Low-Dose Creatine Monohydrate","EXPERIMENTAL","Participants consume 5 grams per day of creatine monohydrate for 28 consecutive days.",[48],"Dietary Supplement: Creatine Monohdyrate",{"label":50,"type":45,"description":51,"interventionNames":52},"High-dose Creatine Monohydrate","Participants consume 10 grams per day of creatine monohydrate for 28 consecutive days.",[48],[54],{"type":55,"name":56,"description":57,"armGroupLabels":58,"otherNames":31},"DIETARY_SUPPLEMENT","Creatine Monohdyrate","Creatine monohydrate taken daily mixed with 6-8 oz of water.",[50,44],[60],{"name":61,"affiliation":5,"role":62},"Abbie Smith-Ryan, PhD","PRINCIPAL_INVESTIGATOR",[64,68],{"name":61,"role":65,"phone":66,"phoneExt":31,"email":67},"CONTACT","919-962-2574","abbiesmith@unc.edu",{"name":69,"role":65,"phone":70,"phoneExt":31,"email":71},"Research Coordinator","919-962-1663","aplresearch@unc.edu",[73],{"facility":74,"status":31,"city":75,"state":76,"zip":77,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":85,"contacts":86},"Applied Physiology Laboratory","Chapel Hill","North Carolina","27599","United States","US",{"type":81,"coordinates":82},"Point",[83,84],-79.05584,35.9132,{"lat":84,"lon":83},[87,89],{"name":88,"role":65,"phone":70,"phoneExt":31,"email":71},"Study Coordinator",{"name":61,"role":62,"phone":31,"phoneExt":31,"email":31},{"type":91,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100654009","creatine-for-recovery-and-thinking-in-mothers-100654009",false,"NCT07795853","Creatine for Recovery and Thinking in Mothers","Creatine for Recovery, Executive Function, Activity, Thinking & Energy in Mothers (CREATE-MOM)","CREATE-MOM","Inclusion Criteria:\n\n* 6 weeks -12 months postpartum\n* Body mass index of 18.5-34.9 kg\u002Fm2\n* Cleared to resume physical activity\n\nExclusion Criteria:\n\n* Experienced a musculoskeletal injury, excluding a Cesarean delivery,within the past three months that inhibits participation in the study.\n* Has chronic kidney disease, liver disease, chronic obstructive pulmonary disease, or cancer\n* Currently using medications that may directly impact the primary outcomes including: diuretics and corticosteroids).\n* Has uncontrolled hypertension or diabetes, or has recently started medication, without a stable dose for 3 consecutive months.\n* Currently using creatine monohydrate or other performance-enhancing supplements\n* Has a self-identified or clinically diagnosed eating disorder\n* Taking or having supplemented with creatine monohydrate in the last 28-days\n* Medical contradictions for physical exercise\n* Has participated in another clinical trial within 4-weeks prior to enrollment that in the opinion of the PI would influence the results.\n* Has severely impaired hearing or speech or inability to speak English.\n* Unwilling or unable to comply with the study protocol, including abstaining from caffeine, tobacco, alcohol, and physical activity before testing days.\n* Is currently pregnant.\n* Has a known allergy to the transducer gel used for the ultrasound\n* Has a known allergy to creatine monohydrate","FEMALE","18 Years","45 Years",{"count":104,"type":105},40,"ESTIMATED","INTERVENTIONAL",[108],"NA","The purpose of this randomized, double-blind, parallel-group trial is to compare the effects of two doses of creatine monohydrate (5 g\u002Fday versus 10 g\u002Fday) administered for four weeks in postpartum women. The study will evaluate exercise performance, post-exercise recovery, cognitive function, and brain creatine concentrations in a sub-sample.",[111,112],"Post-partum","Women",[114,115,116,117,118,119],"exercise","creatine monohydrate","post-partum","women's health","recovery","cognition","NOT_YET_RECRUITING","2026-08-26",{"date":123,"type":124},"2026-08-31","ACTUAL",{"date":126,"type":105},"2026-09-08",{"date":128,"type":105},"2027-05-10",{"name":5,"class":6},1]